Breast Health and Risk Assessment for Hereditary Breast Cancer - - PowerPoint PPT Presentation

▶
breast health and risk assessment for
SMART_READER_LITE
LIVE PREVIEW

Breast Health and Risk Assessment for Hereditary Breast Cancer - - PowerPoint PPT Presentation

Mar 05, 2024 277 likes •735 views

Breast Health and Risk Assessment for Hereditary Breast Cancer Syndromes Imagine Healthy Communities Karinn Chambers, MD FACS Assistant Professor Dept of General Surgery Medical Director Texas Tech Physicians of El Paso Breast Care Center

slide-1
SLIDE 1

Breast Health and Risk Assessment for Hereditary Breast Cancer Syndromes

Imagine Healthy Communities Karinn Chambers, MD FACS Assistant Professor Dept of General Surgery Medical Director Texas Tech Physicians of El Paso Breast Care Center

slide-2
SLIDE 2

Common Questions.

  • What causes breast cancer?
  • Could I have done something to prevent my

breast cancer?

  • How will this affect my daughters risk of

breast cancer development?

  • Will I die from this?
  • Why me?
slide-3
SLIDE 3

What causes breast cancer?

slide-4
SLIDE 4

Could I have prevented this?

  • Unfortunately not…
  • Risk Factors are:

– Obesity – Family history – Hormonal history – Alcohol consumption

slide-5
SLIDE 5

How will this affect my daughters risk?

  • Most breast cancers develop spontaneously

– Only 10% are related to genetic predispositions

  • Most breast cancers occur in the absence of

a family history

  • In the absence of a genetic predisposition,

risk is only slightly greater than average

slide-6
SLIDE 6

Will I die from this?

  • Breast Cancer Survival Rates at 5 years

– Stage 0: 100% – Stage I: 100% – Stage IIA: 93% – Stage IIB: 81% – Stage III: 72% – Stage IV: 24.3%

slide-7
SLIDE 7

Why me?

slide-8
SLIDE 8

Fact or Fiction?

  • If I am diagnosed with breast cancer I will

die from it

  • I can’t get breast cancer if it doesn’t run in

my family

  • I do not need to get yearly mammograms
  • Mammograms can cause breast cancer
slide-9
SLIDE 9

Fact or Fiction?

  • If I am diagnosed with breast cancer I will

need to have a mastectomy

  • If I have a mastectomy my breast cancer will

not come back

  • After breast cancer treatment I will be less of

a woman

  • My spouse will not be able to look me in the

same way after treatment

slide-10
SLIDE 10

Fact or Fiction?

  • If I am diagnosed with breast cancer I will

need chemotherapy

  • I will lose my hair during chemotherapy
  • I will be sick and bed ridden during

chemotherapy

  • I wont be able to work during chemotherapy
slide-11
SLIDE 11

Breast Cancer Screening Protocols, High Risk Screening, Genetic Testing, Diagnosis and Staging.

slide-12
SLIDE 12

Risk Assessment

  • Take a thorough breast history

– Current breast complaints/symptoms

  • Skin changes, nipple retraction, nipple discharge, masses

– Past breast problems

  • Prior biopsies and resulting pathology if known

– ADH/ALH – Number of biopsies

– Family history of breast, ovarian, colon, and pancreatic Ca. – Hormonal History – Age of menarche – Age of 1st child – OCP’s/HRT

slide-13
SLIDE 13

Screening Protocols Continued

  • USPTF (2009):
  • Biennial screening for women age 50-74.
  • At physician discretion for women age 40-74.
  • No screening for women over the age of 75.
  • ACS:
  • Shared decision making process for women ages

40-44.

  • Annual screening for Woman age 45-54
  • Biennial screening for women over the age of 55.
  • Continue screening as long as they have an

estimated 10 year life expectancy.

slide-14
SLIDE 14

Screening Protocols Continued

  • American Society of Breast Surgeons(2015):
  • Discussion with her physician to consider

screening mammography at age 40-44 .

  • Annual Screening for women ages 45-54.
  • Annual or Biennial screening for women 55

and older based on a shared decision making.

  • Biennial screening for women over the age of

75 if an estimated life expectancy is greater than 10 years.

slide-15
SLIDE 15

Screening Protocols Continued

  • American Society of Breast Surgeons (2019):
  • Women age >25 should undergo formal risk

assessment for breast cancer.

  • Women with an average risk of breast cancer

should initiate yearly screening mammography at age 40.

  • Women with a higher-than-average risk of breast

cancer should undergo yearly screening mammography and be offered yearly supplemental imaging; this screening should be initiated at a risk-based age.

  • Screening mammography should cease when life

expectancy is less then 10 yrs.

slide-16
SLIDE 16

Gail Model of Risk Assessment

https://www.cancer.gov/bcrisktool/

  • Includes personal history and hormonal

history

  • Includes 1st degree relatives
  • Includes ethnicity
  • Excludes those BRCA (+) or with history of

DCIS, IDC, or LCIS

slide-17
SLIDE 17

Gail Model

slide-18
SLIDE 18

Tyrer-Cusick Model

http://www.ems-trials.org/riskevaluator/

  • Includes personal and hormonal history

– Hgt/Wgt

  • Includes 1st,2nd, and 3rd degree relatives
  • Includes genetic testing
slide-19
SLIDE 19

Tyrer-Cusick Model

slide-20
SLIDE 20

Who is at High Risk for Breast Cancer?

  • Risk assessment model reveals a greater than 20%

lifetime risk for the development of breast cancer or greater than 1.7% 5 year risk

  • Those individuals who underwent thoracic radiation

between 10 and 30 years of age.

– Annual Mammography – Annual MRI – Biannual clinical exam – Chemoprevention

slide-21
SLIDE 21

High Risk Surveillance

slide-22
SLIDE 22

Genetic Testing (Automatic testing criteria)

  • Affected patient meeting the following

criteria:

– <50 years of age – Triple (-) breast cancer <60 years of age. – Known familial genetic mutation – Two breast cancers – Male patient with breast cancer – An individual with ovarian cancer

slide-23
SLIDE 23

Genetic Testing (Cont.)

  • Breast cancer at any age and…

– One close relative with breast cancer <50 – One close relative with ovarian cancer – 2 or more close relatives with breast cancer and/or pancreatic cancer – From a high risk population

slide-24
SLIDE 24

Genetic Testing Criteria

slide-25
SLIDE 25

Genetic Mutations

  • High Risk

– BRCA1/BRCA2 (Chromosome 17 and 13)

  • Breast and ovarian cancer
  • AD inheritance of variable penetrance

– CDH-1

  • ILC and gastric cancer

– Li-Fraumeni (TP53)

  • Breast cancer, osteosarcomas, soft-tissue sarcomas, young age of onset

– Cowden Syndrome (PTEN)

  • Breast cancer, thyroid cancer, uterine cancer

– PALB2 – ATM* – CHEK2* – STK11*

slide-26
SLIDE 26

BRCA 1 vs. BRCA 2

  • BRCA 1

– Greater risk of ovarian Ca – Greater number of TN breast cancer – Very responsive to therapy with cisplatin like agents

  • BRCA 2

– Greater incidence in men with breast Ca – Present more like sporadic breast Ca cases

slide-27
SLIDE 27

What to do With the Genetic Mutations Found?

slide-28
SLIDE 28
slide-29
SLIDE 29
slide-30
SLIDE 30

Diagnosis

  • Self-Exam
  • Clinical Exam
  • Radiologic Evaluation
  • Mammogram

– Screening – Diagnostic

  • Ultrasound
  • MRI
slide-31
SLIDE 31

Breast Biopsy

  • Self-Exam
  • Clinical Exam
  • Radiologic Evaluation
  • Mammogram

– Screening – Diagnostic

  • Ultrasound
  • MRI
slide-32
SLIDE 32

Why Image Guided Biopsy?

  • Why would we offer this?
  • Establish Dx prior to intervention
  • Differentiate between benign/malignant lesions
  • Once Dx established, allows for treatment planning
  • Neoadjuvant vs adjuvant chemotherapy
  • Asses necessity of other imaging modalities prior to OR
  • Allow for appropriate pre-op consultations

– PRS – Genetics – Fertility preservation

  • Pre-operative axillary assessment/staging
  • Minimize number of interventions
slide-33
SLIDE 33
slide-34
SLIDE 34
slide-35
SLIDE 35
slide-36
SLIDE 36
slide-37
SLIDE 37

Breast Biopsy Cont.

  • Surgical Biopsy

– Needle localized excisional biopsy

  • Uses image guidance to localize the lesion then patient is taken

to the operating room for excision.

  • Used for benign high risk lesions and/or discordant pathological

findings

– Open excisional biopsy

  • Patient taken to the OR then lesion removed via palpation
  • Only utilized for lesions not amenable to image guided biopsy or

those strongly felt to be benign

slide-38
SLIDE 38

Staging

  • T

– Tumor size

  • N

– Lymph node involvement

  • M

– Metastasis

  • Addressed via AJCC guidelines
slide-39
SLIDE 39

Tumor Size

slide-40
SLIDE 40

Clinical Nodal Assessment

slide-41
SLIDE 41

Clinical Stage

slide-42
SLIDE 42
slide-43
SLIDE 43
slide-44
SLIDE 44

Issues You Would Like Discussed?

slide-45
SLIDE 45

Thank you, and hope to see you next time.